Aberrant O-GlcNAcylated proteins: New perspectives in breast and colorectal cancer

Frontiers in Endocrinology

Volumn 5, Issue NOV, 2014, Pages

  Chaiyawat, Parunya ^a   Netsirisawan, Pukkavadee ^a   Svasti, Jisnuson ^a,b   Champattanachai, Voraratt ^a,b  

^a Research and Innovation   (Thailand)

^b Krung Thep Maha Nakhon   (Thailand)

Author keywords

Breast cancer; Cancer biomarker; Colorectal cancer; Hexosamine biosynthesis pathway; O GlcNAcylation; Phosphorylation

Indexed keywords

1 PHOSPHOFRUCTOKINASE; BETA CATENIN; CAVEOLIN 1; CYTOKERATIN 8; ENOLASE; GLUCOSE TRANSPORTER 1; GLUTAMINE; GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 27; HEXOSAMINE; HISTONE DEACETYLASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P120; PROTEIN P50; PROTEIN P53; PYRUVATE KINASE; THYMIDINE PHOSPHORYLASE; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SP1; TRIOSEPHOSPHATE ISOMERASE; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE; UVOMORULIN; VIMENTIN; VOLTAGE DEPENDENT ANION CHANNEL 1;

BREAST CANCER; CANCER GROWTH; CITRIC ACID CYCLE; COLORECTAL CANCER; COMPLEX FORMATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOKINE PRODUCTION; DRUG TARGETING; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE SILENCING; GLUCOSE INTAKE; GLUCOSE METABOLISM; GLYCOSYLATION; HEPG2 CELL LINE; HUMAN; HYPERGLYCEMIA; LUNG CANCER CELL LINE; ONCOGENE C MYC; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; REVIEW; RNA INTERFERENCE; RNA PROCESSING; TUMOR GROWTH;

EID: 84920186308     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00193     Document Type: Review

References (91)

1. Warburg O. Origin of cancer cells. Oncologia (1956) 9(2):75-83. doi:10.1159/000223920
2. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 11(2):85-95. doi:10.1038/nrc2981
3. DeBerardinis RJ. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med (2008) 10(11):767-77. doi:10.1097/GIM.0b013e31818b0d9b
4. Chowdhury FU, Shah N, Scarsbrook AF, Bradley KM. [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. Postgrad Med J (2010) 86(1013):174-82. doi:10.1136/pgmj.2009.079087
5. Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem (1984) 259(5):3308-17.
6. Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem (1997) 272(14):9308-15. doi:10.1074/jbc.272.14.9308
7. Gao Y, Wells L, Comer FI, Parker GJ, Hart GW. Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J Biol Chem (2001) 276(13):9838-45. doi:10.1074/jbc. M010420200
8. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature (2007) 446(7139):1017-22. doi:10.1038/nature05815
9. Ma J, Hart GW. O-GlcNAc profiling: from proteins to proteomes. Clin Proteomics (2014) 11(1):8. doi:10.1186/1559-0275-11-8
10. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem (2011) 80:825-58. doi:10.1146/annurev-biochem-060608-102511
11. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem (1991) 266(8):4706-12.
12. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem (2000) 275(29):21797-800. doi:10.1074/jbc. C000023200
13. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 149(3):656-70. doi:10.1016/j.cell.2012.01.058
14. Manzari B, Kudlow JE, Fardin P, Merello E, Ottaviano C, Puppo M, et al. Induction of macrophage glutamine: fructose-6-phosphate amidotransferase expression by hypoxia and by picolinic acid. Int J Immunopathol Pharmacol (2007) 20(1):47-58.
15. Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezène P, et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2013) 110(10):3919-24. doi:10.1073/pnas.1219555110
16. Uldry M, Ibberson M, Hosokawa M, Thorens B. GLUT2 is a high affinity glucosamine transporter. FEBS Lett (2002) 524(1-3):199-203. doi:10.1016/S0014-5793(02)03058-2
17. Yang DJ, Kong FL, Oka T, Bryant JL. Molecular imaging kits for hexosamine biosynthetic pathway in oncology. Curr Med Chem (2012) 19(20):3310-4. doi:10.2174/092986712801215900
18. Li Z, Yi W. Regulation of cancer metabolism by O-GlcNAcylation. Glycoconj J (2014) 31(3):185-91. doi:10.1007/s10719-013-9515-5
19. Ma Z, Vosseller K. O-GlcNAc in cancer biology. Amino Acids (2013) 45(4):719-33. doi:10.1007/s00726-013-1543-8
20. Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA III, et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science (2012) 337(6097):975-80. doi:10.1126/science.1222278
21. Nandi A, Sprung R, Barma DK, Zhao Y, Kim SC, Falck JR, et al. Global identification of O-GlcNAc-modified proteins. Anal Chem (2006) 78(2):452-8. doi:10.1021/ac051207j
22. Dehennaut V, Slomianny MC, Page A, Vercoutter-Edouart AS, Jessus C, Michalski JC, et al. Identification of structural and functional O-linked N-acetylglucosamine-bearing proteins in Xenopus laevis oocyte. Mol Cell Proteomics (2008) 7(11):2229-45. doi:10.1074/mcp. M700494-MCP200
23. Jones SP, Zachara NE, Ngoh GA, Hill BG, Teshima Y, Bhatnagar A, et al. Cardioprotection by N-acetylglucosamine linkage to cellular proteins. Circulation (2008) 117(9):1172-82. doi:10.1161/CIRCULATIONAHA.107.730515
24. Wang Z, Pandey A, Hart GW. Dynamic interplay between O-GlcNAcylation and GSK-3-dependent phosphorylation. Mol Cell Proteomics (2007) 6(8):1365-79. doi:10.1074/mcp. M600453-MCP200
25. Champattanachai V, Netsirisawan P, Chaiyawat P, Phueaouan T, Charoenwattanasatien R, Chokchaichamnankit D, et al. Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer. Proteomics (2013) 13(14):2088-99. doi:10.1002/pmic.201200126
26. Rambaruth ND, Greenwell P, Dwek MV. The lectin Helix pomatia agglutinin recognizes O-GlcNAc containing glycoproteins in human breast cancer. Glycobiology (2012) 22(6):839-48. doi:10.1093/glycob/cws051
27. Di Domenico F, Owen JB, Sultana R, Sowell RA, Perluigi M, Cini C, et al. The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: implications for disease pathogenesis and progression. J Neurosci Res (2010) 88(16):3566-77. doi:10.1002/jnr.22528
28. Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood (2013) 122(20):3521-32. doi:10.1182/blood-2013-03-493163
29. Shimizu K, Kaira K, Tomizawa Y, Sunaga N, Kawashima O, Oriuchi N, et al. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. Br J Cancer (2014) 110(8):2030-9. doi:10.1038/bjc.2014.88
30. Ma Z, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-kappaB activity in pancreatic cancer cells. J Biol Chem (2013) 288(21):15121-30. doi:10.1074/jbc. M113.470047
31. Donadio AC, Lobo C, Tosina M, de la Rosa V, Martín-Rufián M, Campos-Sandoval JA, et al. Antisense glutaminase inhibition modifies the O-GlcNAc pattern and flux through the hexosamine pathway in breast cancer cells. J Cell Biochem (2008) 103(3):800-11. doi:10.1002/jcb.21449
32. Matés JM, Segura JA, Alonso FJ, Márquez J. Pathways from glutamine to apoptosis. Front Biosci (2006) 11:3164-80. doi:10.2741/2040
33. Butkinaree C, Park K, Hart GW. O-linked beta-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta (2010) 1800(2):96-106. doi:10.1016/j.bbagen.2009.07.018
34. Hanover JA, Yu S, Lubas WB, Shin SH, Ragano-Caracciola M, Kochran J, et al. Mitochondrial and nucleocytoplasmic isoforms of O-linked GlcNAc transferase encoded by a single mammalian gene. Arch Biochem Biophys (2003) 409(2):287-97. doi:10.1016/S0003-9861(02)00578-7
35. Jeon JH, Suh HN, Kim MO, Han HJ. Glucosamine-induced reduction of integrin beta4 and plectin complex stimulates migration and proliferation in mouse embryonic stem cells. Stem Cells Dev (2013) 22(22):2975-89. doi:10.1089/scd.2013.0158
36. Jin FZ, Yu C, Zhao DZ, Wu MJ, Yang Z. A correlation between altered O-GlcNAcylation, migration and with changes in E-cadherin levels in ovarian cancer cells. Exp Cell Res (2013) 319(10):1482-90. doi:10.1016/j.yexcr.2013.03.013
37. Dorfmueller HC, Borodkin VS, Schimpl M, van Aalten DM. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation. Biochem J (2009) 420(2):221-7. doi:10.1042/BJ20090110
38. Cheung WD, Sakabe K, Housley MP, Dias WB, Hart GW. O-linked beta-N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. J Biol Chem (2008) 283(49):33935-41. doi:10.1074/jbc. M806199200
39. Whisenhunt TR, Yang X, Bowe DB, Paterson AJ, Van Tine BA, Kudlow JE. Disrupting the enzyme complex regulating O-GlcNAcylation blocks signaling and development. Glycobiology (2006) 16(6):551-63. doi:10.1093/glycob/cwj096
40. Phueaouan T, Chaiyawat P, Netsirisawan P, Chokchaichamnankit D, Punyarit P, Srisomsap C, et al. Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer. Oncol Rep (2013) 30(6):2929-36. doi:10.3892/or.2013.2794
41. Bachmaier R, Aryee DN, Jug G, Kauer M, Kreppel M, Lee KA, et al. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma. Oncogene (2009) 28(9):1280-4. doi:10.1038/onc.2008.484
42. Rozanski W, Krzeslak A, Forma E, Brys M, Blewniewski M, Wozniak P, et al. Prediction of bladder cancer based on urinary content of MGEA5 and OGT mRNA level. Clin Lab (2012) 58(5-6):579-83.
43. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, et al. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene (2010) 29(19):2831-42. doi:10.1038/onc.2010.41
44. Gu Y, Mi W, Ge Y, Liu H, Fan Q, Han C, et al. GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res (2010) 70(15):6344-51. doi:10.1158/0008-5472.CAN-09-1887
45. Drougat L, Olivier-Van Stichelen S, Mortuaire M, Foulquier F, Lacoste AS, Michalski JC, et al. Characterization of O-GlcNAc cycling and proteomic identification of differentially O-GlcNAcylated proteins during G1/S transition. Biochim Biophys Acta (2012) 1820(12):1839-48. doi:10.1016/j.bbagen.2012.08.024
46. Phoomak C, Silsirivanit A, Wongkham C, Sripa B, Puapairoj A, Wongkham S. Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma. Asian Pac J Cancer Prev (2012) 13(Suppl):101-5. doi:10.7314/APJCP.2012.13.KKSuppl.101
47. Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X, et al. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta (2011) 1812(4):514-9. doi:10.1016/j.bbadis.2011.01.009
48. Yehezkel G, Cohen L, Kliger A, Manor E, Khalaila I. O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-beta-d-glucosaminidase silencing on cell phenotype and transcriptome. J Biol Chem (2012) 287(34):28755-69. doi:10.1074/jbc. M112.345546
49. Olivier-Van Stichelen S, Dehennaut V, Buzy A, Zachayus JL, Guinez C, Mir AM, et al. O-GlcNAcylation stabilizes beta-catenin through direct competition with phosphorylation at threonine 41. FASEB J (2014) 28(8):3325-38. doi:10.1096/fj.13-243535
50. Shi Y, Tomic J, Wen F, Shaha S, Bahlo A, Harrison R, et al. Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia (2010) 24(9):1588-98. doi:10.1038/leu.2010.152
51. Zhu Q, Zhou L, Yang Z, Lai M, Xie H, Wu L, et al. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol (2012) 29(2):985-93. doi:10.1007/s12032-011-9912-1
52. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem (2012) 287(14):11070-81. doi:10.1074/jbc. M111.302547
53. Kamigaito T, Okaneya T, Kawakubo M, Shimojo H, Nishizawa O, Nakayama J. Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis (2014) 17(1):18-22. doi:10.1038/pcan.2013.56
54. Krzeslak A, Pomorski L, Lipinska A. Elevation of nucleocytoplasmic beta-N-acetylglucosaminidase (O-GlcNAcase) activity in thyroid cancers. Int J Mol Med (2010) 25(4):643-8. doi:10.3892/ijmm_00000387
55. Lazarus MB, Nam Y, Jiang J, Sliz P, Walker S. Structure of human O-GlcNAc transferase and its complex with a peptide substrate. Nature (2011) 469(7331):564-7. doi:10.1038/nature09638
56. Dias WB, Cheung WD, Hart GW. O-GlcNAcylation of kinases. Biochem Biophys Res Commun (2012) 422(2):224-8. doi:10.1016/j.bbrc.2012.04.124
57. Hu P, Shimoji S, Hart GW. Site-specific interplay between O-GlcNAcylation and phosphorylation in cellular regulation. FEBS Lett (2010) 584(12):2526-38. doi:10.1016/j.febslet.2010.04.044
58. Zeidan Q, Hart GW. The intersections between O-GlcNAcylation and phosphorylation: implications for multiple signaling pathways. J Cell Sci (2010) 123(Pt 1):13-22. doi:10.1242/jcs.053678
59. Chou TY, Hart GW, Dang CV. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem (1995) 270(32):18961-5. doi:10.1074/jbc.270.32.18961
60. Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS, et al. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol (2006) 8(10):1074-83. doi:10.1038/ncb1470
61. Park SY, Kim HS, Kim NH, Ji S, Cha SY, Kang JG, et al. Snail1 is stabilized by O-GlcNAc modification in hyperglycaemic condition. EMBO J (2010) 29(22):3787-96. doi:10.1038/emboj.2010.254
62. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood (2000) 95(6):2104-10.
63. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 6(10):931-40. doi:10.1038/ncb1173
64. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol (2009) 1(5):a000141. doi:10.1101/cshperspect.a000141
65. Wang Z, Udeshi ND, Slawson C, Compton PD, Sakabe K, Cheung WD, et al. Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates cytokinesis. Sci Signal (2010) 3(104):ra2. doi:10.1126/scisignal.2000526
66. Slawson C, Lakshmanan T, Knapp S, Hart GW. A mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin. Mol Biol Cell (2008) 19(10):4130-40. doi:10.1091/mbc. E07-11-1146
67. Guo K, Gan L, Zhang S, Cui FJ, Cun W, Li Y, et al. Translocation of HSP27 into liver cancer cell nucleus may be associated with phosphorylation and O-GlcNAc glycosylation. Oncol Rep (2012) 28(2):494-500. doi:10.3892/or.2012.1844
68. Srikanth B, Vaidya MM, Kalraiya RD. O-GlcNAcylation determines the solubility, filament organization, and stability of keratins 8 and 18. J Biol Chem (2010) 285(44):34062-71. doi:10.1074/jbc. M109.098996
69. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014). doi:10.1002/ijc.29210
70. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 319(9):525-32. doi:10.1056/NEJM198809013190901
71. Ha JR, Hao L, Venkateswaran G, Huang YH, Garcia E, Persad S. Beta-catenin is O-GlcNAc glycosylated at Serine 23: implications for beta-catenin's subcellular localization and transactivator function. Exp Cell Res (2014) 321(2):153-66. doi:10.1016/j.yexcr.2013.11.021
72. Olivier-Van Stichelen S, Guinez C, Mir AM, Perez-Cervera Y, Liu C, Michalski JC, et al. The hexosamine biosynthetic pathway and O-GlcNAcylation drive the expression of beta-catenin and cell proliferation. Am J Physiol Endocrinol Metab (2012) 302(4):E417-24. doi:10.1152/ajpendo.00390.2011
73. Roy HK, Smyrk TC, Koetsier J, Victor TA, Wali RK. The transcriptional repressor SNAIL is overexpressed in human colon cancer. Dig Dis Sci (2005) 50(1):42-6. doi:10.1007/s10620-005-1275-z
74. Becker KF, Rosivatz E, Blechschmidt K, Kremmer E, Sarbia M, Höfler H. Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs (2007) 185(1-3):204-12. doi:10.1159/000101321
75. Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res (2008) 28(6A):3815-26.
76. Han I, Kudlow JE. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol (1997) 17(5):2550-8.
77. Haltiwanger RS, Grove K, Philipsberg GA. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-d-glucopyranosylidene)amino-N-phenylcarbamate. J Biol Chem (1998) 273(6):3611-7. doi:10.1074/jbc.273.6.3611
78. Guinez C, Mir AM, Dehennaut V, Cacan R, Harduin-Lepers A, Michalski JC, et al. Protein ubiquitination is modulated by O-GlcNAc glycosylation. FASEB J (2008) 22(8):2901-11. doi:10.1096/fj.07-102509
79. Ku NO, Omary MB. Identification and mutational analysis of the glycosylation sites of human keratin 18. J Biol Chem (1995) 270(20):11820-7. doi:10.1074/jbc.270.20.11820
80. Walgren JL, Vincent TS, Schey KL, Buse MG. High glucose and insulin promote O-GlcNAc modification of proteins, including alpha-tubulin. Am J Physiol Endocrinol Metab (2003) 284(2):E424-34. doi:10.1152/ajpendo.00382.2002
81. Ji S, Kang JG, Park SY, Lee J, Oh YJ, Cho JW. O-GlcNAcylation of tubulin inhibits its polymerization. Amino Acids (2011) 40(3):809-18. doi:10.1007/s00726-010-0698-9
82. Slawson C, Pidala J, Potter R. Increased N-acetyl-beta-glucosaminidase activity in primary breast carcinomas corresponds to a decrease in N-acetylglucosamine containing proteins. Biochim Biophys Acta (2001) 1537(2):147-57. doi:10.1016/S0925-4439(01)00067-9
83. Dahl E, Sadr-Nabavi A, Klopocki E, Betz B, Grube S, Kreutzfeld R, et al. Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol (2005) 205(1):21-8. doi:10.1002/path.1687
84. Krzeslak A, Forma E, Bernaciak M, Romanowicz H, Brys M. Gene expression of O-GlcNAc cycling enzymes in human breast cancers. Clin Exp Med (2012) 12(1):61-5. doi:10.1007/s10238-011-0138-5
85. Kanwal S, Fardini Y, Pagesy P, N'Tumba-Byn T, Pierre-Eugène C, Masson E, et al. O-GlcNAcylation-inducing treatments inhibit estrogen receptor alpha expression and confer resistance to 4-OH-tamoxifen in human breast cancer- derived MCF-7 cells. PLoS One (2013) 8(7):e69150. doi:10.1371/journal.pone.0069150
86. Zhu W, Leber B, Andrews DW. Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. EMBO J (2001) 20(21):5999-6007. doi:10.1093/emboj/20.21.5999
87. Geng F, Zhu W, Anderson RA, Leber B, Andrews DW. Multiple post-translational modifications regulate E-cadherin transport during apoptosis. J Cell Sci (2012) 125(Pt 11):2615-25. doi:10.1242/jcs.096735
88. Huang X, Pan Q, Sun D, Chen W, Shen A, Huang M, et al. O-GlcNAcylation of cofilin promotes breast cancer cell invasion. J Biol Chem (2013) 288(51):36418-25. doi:10.1074/jbc. M113.495713
89. Komura K, Ise H, Akaike T. Dynamic behaviors of vimentin induced by interaction with GlcNAc molecules. Glycobiology (2012) 22(12):1741-59. doi:10.1093/glycob/cws118
90. Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL, et al. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell (2014) 54(5):820-31. doi:10.1016/j.molcel.2014.04.026
91. Chu CS, Lo PW, Yeh YH, Hsu PH, Peng SH, Teng YC, et al. O-GlcNAcylation regulates EZH2 protein stability and function. Proc Natl Acad Sci U S A (2014) 111(4):1355-60. doi:10.1073/pnas.1323226111